The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodeg...
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: PR Newswire
With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach USD 4 billion by 2034. Key players driving this expansion include Iovance Biotherapeutics, Eisai, Citius Pharmaceuticals, Nektar Therapeutics, Mural Oncology, Corvus Pharmaceuticals, and Krystal Biotech, among others.LAS VEGAS, March 27, 2025 /PRNewswire/ --Key HighlightsThe total treatment-eligible cases for IL-2 therapies are approximately 13.6 million in the 7MM in 2024. This patient segment comprises an eligible population from 13 leading indications where either IL-2 therapy has been approved or is in clinical trials. The list of indications includes Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL)Non-segmental Vitiligo (NSV), Aplastic Anemia, Amyotrophic Lateral Sclerosis (ALS), Ovarian cancer, Head and neck squamous cell carcinoma (HNSCC), Melanoma, Atopic Dermatitis, Alopecia Areata, Non-small cell lung cancer (NSCLC), and Mucosal Melanoma.In t
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
- Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]Seeking Alpha
- Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma gains amid takeover speculation [Seeking Alpha]Seeking Alpha
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.MarketBeat
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 12/10/25 - Form 6-K
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- ASND's page on the SEC website